Last reviewed · How we verify
E1224
At a glance
| Generic name | E1224 |
|---|---|
| Also known as | E1224 (prodrug for active ingredient Ravuconazole), Fosravuconazole, Placebo (for E1224), E1224 is a prodrug monolysine form of ravuconazole. |
| Sponsor | Drugs for Neglected Diseases |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan (PHASE2)
- Pharmacokinetic Drug-Drug Interaction Study (PHASE1)
- BENDITA BEnznidazole New Doses Improved Treatment and Associations (PHASE2)
- Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E1224 CI brief — competitive landscape report
- E1224 updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI